Add To Watchlist
Share URL
About The Company
CEO
Mr. Karim Bitar
Market Cap
5.62 Billion GBp
Sector
Healthcare
Website
https://www.convatecgroup.comLast Update
02/04/2025, 17:32:32
Description
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide.
Read More
Overview
Value
9
Growth
47
Health
48
Management
52
Analyst Opinion
29
Total
37
All Scores Out Of 100
Best Features
- Has a low level of debt
- Low risk of bankruptcy
- Has strong dividend growth
Risk Factors
- Overvalued on cashflow basis
- Earnings growth has slowed down recently
- There is a history of diluting shareholders
- No margin of safety at their current market price
- Disliked by Twitter users
- Price-to-earnings ratio of 30.5 is higher than the market average (19.6x)
- High preportion of income is paid as dividend
Market Peers
CTEC.L
Key Figures
PE Ratio (TTM)
30.47
Margin Of Safety (DCF)
-98.58%
Revenue Growth (5 Year Average)
2.44%
Ratings Consensus
Strong Sell
Share Buybacks
-0.51%
Dividend Yeild (TTM)
0.03%
Valuation
Value Score
9
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 0.4 GBp ✘
Current Price: 254.6 GBp
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
30.47x
Free Cashflow Yeild
0.05%
PE/Earnings Growth
5.48
Price/Book
30734.93x
Growth
Growth Score
47
- ✔ Revenue growth has improved this yeara
- ✔ 5 Year Average Earnings growth of 18.67% is higher than the market average (14.48%)
- ✘ 5 Year Average Revenue growth of 2.44% is lower than the market average (10.97%)
- ✘ Earnings growth has slowed this year
- ✘ 5 Year Average Free Cashflow growth of 9.48% is lower than the market average (12.35%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
2.44%
Earnings Growth
18.67%
Cashflow Growth
9.48%
Health
Health Score
48
Altman Z Score
3.21
Piostroski Score
6.00
Debt/Equity
0.71x
Current Assets/Liabilities
1.55x
Free Cashflow/Total Debt
0.02x
Debt/Capital
1.51x
Dividend
Secure Dividend Score
48
- ✘ At risk of being unsafe
- ✔ Dividends have shown growth over the last 5 years
- ✔ Dividend growth has been accelerating recently
- ✘ Dividend yeild of 0.03% is less than the market average (1.85%)
- ✘ Long term dividend payout ratio of 88.56% is high and may limit growth
- ✘ Payout ratio (TTM) of 103.53% is higher than the average (40%)
- ✘ Spending a higher percentage of their income on dividends than last 5 years
Dividend Yeild
0.03%
Dividend Growth
25.43%
Payout Ratio (Earnings)
103.53%
Payout Ratio (Cashflow)
70.44%
Management
Management Score
52
- ✔ Has issued new shares to finance growth when share price is high
- ✔ Has returned higher dividends when earnings have risen
- ✔ Return-on-equity of 458.73% is higher than the market average (15%)
- ✘ Return-on-capital-employed of 8.67% is lower than the market average (10%)
- ✘ Has a history of diluting shareholders to finance activity
Average Buybacks/Dilution
-0.51%
Recent Buybacks/Dilution
N/A
5 Year Price Volitility
10.73%
Return On Assets
220.41%
Return On Capital Employed
8.67%
Return On Equity
458.73%
Return On Free Cashflow
N/A
Return On Investments
45843.17%
Analysts
Analyst Opinion
29
- ✘ Ratings consensus is Strong Sell
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
ConvaTec Group Plc
Currency
GBp
Beta
0.707
Vol Avg
6393461
Ceo
Mr. Karim Bitar
Cik
Cusip
G23969101
Exchange
London Stock Exchange
Full Time Employees
10489
Industry
Medical - Instruments & Supplies
Sector
Healthcare
Ipo Date
2016-10-26
Address
3 Forbury Place
City
Reading
State
Country
GB
Zip
RG1 3JH
Phone
44 11 8952 8100
Analysis Last Updated
02/04/2025, 17:32:32
All financial data provided by FMP
Social Sentiment
Social Sentiment Score
0
Twitter Sentiment
N/A
Stocktwits Sentiment
N/A